Kalaris Therapeutics, Inc. (KLRS)
4.08
-0.07
(-1.69%)
USD |
NASDAQ |
Aug 24, 16:00
4.08
0.00 (0.00%)
After-Hours: 20:00
Kalaris Therapeutics Enterprise Value : 6.653M for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 6.653M |
| August 20, 2026 | 5.939M |
| August 19, 2026 | 7.129M |
| August 18, 2026 | 3.796M |
| August 17, 2026 | 2.130M |
| August 14, 2026 | 4.986M |
| August 13, 2026 | 0.2254M |
| August 12, 2026 | 1.654M |
| August 11, 2026 | 2.368M |
| August 10, 2026 | 1.654M |
| August 07, 2026 | 4.748M |
| August 06, 2026 | 7.605M |
| August 05, 2026 | 7.605M |
| August 04, 2026 | 10.70M |
| August 03, 2026 | 4.272M |
| July 31, 2026 | -8.582M |
| July 30, 2026 | -9.297M |
| July 29, 2026 | -11.20M |
| July 28, 2026 | -12.63M |
| July 27, 2026 | -6.916M |
| July 24, 2026 | -3.345M |
| July 23, 2026 | 1.178M |
| July 22, 2026 | 4.748M |
| July 21, 2026 | 4.034M |
| July 20, 2026 | 3.082M |
| Date | Value |
|---|---|
| July 17, 2026 | 12.13M |
| July 16, 2026 | 17.60M |
| July 15, 2026 | 22.60M |
| July 14, 2026 | 16.17M |
| July 13, 2026 | 13.08M |
| July 10, 2026 | 13.56M |
| July 09, 2026 | 14.75M |
| July 08, 2026 | 19.98M |
| July 07, 2026 | 22.84M |
| July 06, 2026 | 18.56M |
| July 02, 2026 | 20.94M |
| July 01, 2026 | 15.70M |
| June 30, 2026 | 4.748M |
| June 29, 2026 | 1.108M |
| June 26, 2026 | 3.522M |
| June 25, 2026 | 3.062M |
| June 24, 2026 | 5.361M |
| June 23, 2026 | 6.971M |
| June 22, 2026 | 5.361M |
| June 18, 2026 | 12.72M |
| June 17, 2026 | 8.81M |
| June 16, 2026 | 4.671M |
| June 15, 2026 | 2.372M |
| June 12, 2026 | 3.752M |
| June 11, 2026 | 4.441M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Replimune Group, Inc. | 1.157B |
| Arrowhead Pharmaceuticals, Inc. | 12.07B |
| Oncolytics Biotech, Inc. | 101.41M |
| Sangamo Therapeutics, Inc. | 50.70M |
| Sarepta Therapeutics, Inc. | 2.242B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -11.52M |
| Total Expenses (Quarterly) | 11.52M |
| EPS Diluted (Quarterly) | -0.4839 |
| Earnings Yield | -49.37% |
| Normalized Earnings Yield | -49.36 |